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Memory B cells provide rapid protection to previously encountered antigens; however, 
how these cells develop from germinal center B cells is not well understood. A previously 
described in vitro culture system using human tonsillar germinal center B cells was used 
to study the transcriptional changes that occur during differentiation of human memory 
B cells. Kinetic studies monitoring the expression levels of several known late B cell transcrip-
tion factors revealed that BCL-6 is not expressed in memory B cells generated in vitro, and 
gene expression profi  ling studies confi  rmed that BCL-6 is not expressed in these memory 
B cells. Furthermore, ectopic expression of BCL-6 in human B cell cultures resulted in forma-
tion of fewer memory B cells. In addition, the expression profi  le of in vitro memory B cells 
showed a unique pattern that includes expression of genes encoding multiple costimulatory 
molecules and cytokine receptors, antiapoptotic proteins, T cell chemokines, and transcrip-
tion factors. These studies establish new molecular criteria for defi  ning the memory B cell 
stage in human B cells.
When B cells respond to a T cell–dependent 
protein antigen, extrafollicular plasma cells ex-
pressing low-affi   nity  B  cell  receptors  (BCRs) 
form early in the primary response. However, 
10–12 d after immunization, after B cell matura-
tion in germinal centers (GCs), two kinds of 
diff  erentiated eff  ectors expressing high affi   nity 
Igs are formed (1). These are non-Ig–secreting 
memory B cells and Ig-secreting plasma cells. 
Memory B cells diff  er from plasma cells in that 
they do not secrete Ig, have a low basal level of 
proliferation, and have the ability to diff  erentiate 
rapidly into Ig-secreting cells after secondary anti-
genic challenge (2). Most plasma cells are short 
lived, although a subset receives survival signals 
in the bone marrow and continues secreting Ig 
for extended periods (3). Transcription factors 
that are critical for the maturation of B cells in 
GCs and for formation and function of plasma 
cells have been identifi  ed. In addition, gene 
expression profi  les GC B cells and plasma cells 
have been determined by several groups (4–7). 
Signifi  cantly less is known about regulation and 
gene expression patterns in memory B cells.
Plasma cell diff  erentiation is under the con-
trol of several transcription factors that coordi-
nately drive terminal diff  erentiation and Ig 
secretion. These transcription factors include 
Blimp-1, IRF-4, and XBP-1 (for review see 
reference 8). The targets of these factors and the 
complex patterns of gene expression in plasma 
cells have been well studied. When plasma cell 
transcription factors are induced, GC or acti-
vated B cell factors such as Bcl-6, Pax5, Bach2, 
MiTF (1, 9), and IRF-8 (10) are repressed. In-
deed, the plasma cell transcription factors and 
the GC transcription factors appear to establish 
mutually exclusive regulatory programs enforced 
by gene repression. For example, in GC B cells 
Bcl-6 represses Prdm1 (encoding Blimp-1) (11), 
BSAP may repress Xbp-1 (12), and MiTF represses 
IRF4 (13), whereas in plasma cells, Blimp-1 re-
presses Bcl-6 and Pax5 (14).
In contrast, much less is known about gene 
expression patterns in memory B cells, and 
transcription factors required for their diff  eren-
tiation have not been identifi  ed. It is known 
that memory B cells have increased expression 
of CD80 and CD86 (15), allowing effi   cient 
costimulation of T helper cells and elevated 
expression of antiapoptotic genes BCL-2 and 
BCL-xL, aiding long-term survival (4, 16). 
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More recently, it was demonstrated that Stat5-dependent 
  induction of BCL-6 in human memory B cells resulted in 
self-renewal properties (17). There is also evidence for diff  er-
ent subsets of memory B cells (for review see reference 18).
Mice lacking Bcl-6 demonstrate that Bcl-6 is required for 
the function of GC B cells (19, 20). However, Bcl-6 may also 
have a role in memory B cells. It has been suggested that 
BCL-6 functions in memory B cells by providing replicative 
potential and repressing terminal diff   erentiation to plasma 
cells (21). Indeed, two studies have demonstrated that ectopic 
expression of BCL-6 in B cells maintains cell survival over a 
long period of time (17, 22). Scheeren et al. demonstrated in 
human B cells that phosphorylated Stat5 directly induces 
BCL-6 expression and that ectopic expression of STAT5 
or BCL-6 in peripheral B cells increased their self-renewal 
capacity (17). However, in Bcl-6−/− mice, functional mem-
ory B cells develop and are capable of responding to second-
ary antigenic stimulation, providing evidence that Bcl-6 is 
not strictly required for memory B cell diff  erentiation  or 
function (23). Additionally, several studies have shown that 
Bcl-6 RNA and protein are expressed primarily in GC B 
cells (10, 24–26). Thus, a role for Bcl-6 in memory B cells is 
still unclear.
We are interested in understanding gene expression 
pat  terns in memory B cells, the role of Bcl-6 in memory 
B cells, and the changes in transcriptional regulators that 
allow GC B cells to diff  erentiate into plasma and memory 
B  cells. Because it is diffi     cult to address these questions 
in vivo, we have taken advantage of an in vitro culture sys-
tem originally described by Choi and colleagues (27–29). In 
this system, centroblasts purifi   ed from human tonsils are 
cultured with CD40L, cytokines, and a follicular dendritic 
cell–like cell line called HK (30), thus mimicking a GC 
environment. The addition of IL-4 into the culture drives 
memory B cell diff  erentiation and the addition of IL-10 
drives plasma cell diff   erentiation (27, 28). Various stages 
of cells in the cultures have been defi  ned previously and 
can be distinguished by fl  ow cytometry: centroblasts are 
CD20hiCD38hi, memory B cells are CD20+CD38−, and 
plasma cells are CD20−CD38+ (29, 31). IL-4 drives the in 
vitro diff  erentiation of human tonsillar GC B cells to memory 
B cells, characterized by surface proteins found on human 
memory B cells that are IgD−CD20+CD38−CD44+CD86+ 
(15, 27). Memory B cells expressing these surface proteins 
in vivo are quiescent, completely isotype switched, have 
hypermutations of the heavy chain locus, and do not secrete 
Ig (15, 32, 33). Additionally, purifi  ed cells with these phe-
notypes produce specifi  c IgG antibodies when challenged 
with tetanus toxoid (15, 29). Although the CD38−CD20+ 
cells in this culture have many characteristics of in vivo mem-
ory B cells, their ability to provide memory in vivo cannot 
be demonstrated. Therefore, we refer to them as in vitro mem-
ory B cells.
Using this culture system, we monitored changes in the 
expression of transcription factors known to be important 
in GC B cells and plasma cells. These studies showed that 
none of the GC or plasma cell transcription factors studied, 
including BCL-6, were induced or highly expressed during 
formation of memory B cells in vitro. Furthermore, ectopic 
expression of BCL-6 in cultured GC B cells blocked the 
  majority of the cells from diff  erentiating into memory B cells 
in response to IL-4, providing evidence that BCL-6 repres-
sion is necessary for in vitro memory B cell diff  erentiation. 
Microarray studies confi  rmed that BCL-6 was not expressed 
in in vitro memory B cells. However, a unique pattern of 
gene expression was identifi  ed for in vitro memory B cells, 
including genes encoding multiple costimulatory molecules 
and cytokine receptors, antiapoptotic proteins, T cell chemo-
kines, and transcription factors.
RESULTS
Changes in transcription factor mRNAs during 
differentiation of memory B cells and plasma cells 
in culture
To explore changes in expression of transcription factors dur-
ing the diff  erentiation of memory B cells and plasma cells, 
we took advantage of a previously described in vitro cul-
ture system for human tonsillar B cells (27–29). This sys-
tem allowed us to compare the kinetics and magnitude of 
changes in gene expression during post-GC diff  erentiation 
of plasma and memory B cells in vitro. As previously re-
ported, purifi  ed human tonsillar centroblasts cultured on HK 
cells (30) with CD40L, IL-2 and IL-4, or IL-10 develop into 
  memory B cells or plasma cells, respectively (28) (Fig. 1 A). 
  Using antibodies to CD20 and CD38, we detected over 90% 
CD20+CD38− memory B cells in cultures of centroblasts 
with IL-4 and at least 70% CD20−CD38+ plasma cells in 
cultures with IL-10 after 10–15 d of culture. For simplicity, 
stimulation of centroblasts with CD40L, IL-2, and IL-4 on 
HK cells will be referred to as the memory B cell culture 
and stimulation with CD40L, IL-2, and IL-10 on HK cells 
will be referred to as the plasma cell culture. Based on previ-
ous studies, CD20hiCD38hi, CD20+CD38+, CD20+CD38−, 
and CD20−CD38+ will be referred to as centroblasts, centro-
cytes, in vitro memory B cells, and plasma cells, respectively. 
Consistent with previous observations, only plasma cell cul-
tures contain substantial levels of IgG in the supernatant (34). 
Compared with memory B cell cultures, plasma cell cultures 
contain 25-fold more IgG secreted into the culture superna-
tant by the end of 10 d (Fig. 1 B).
In vitro memory B cells can quickly diff  erentiate into 
plasma cells upon reculturing with IL-10 instead of IL-4. The 
rapid induction of plasma cells from in vitro memory B cells 
occurs within 2–3 d compared with 5–10 d required for the 
diff  erentiation of centroblasts into plasma cells (Fig. 1 C) (28). 
This is consistent with the characteristics of in vivo memory 
B cells, which undergo rapid plasmacytic diff  erentiation upon 
challenge (35, 36).
Changes in steady-state mRNAs encoding key trans-
cription factors during the diff  erentiation of centroblasts 
to in vitro memory B and plasma cells were monitored by 
quantitative RT-PCR, normalized to cyclophilin A, and JEM VOL. 204, April 16, 2007  821
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compared with levels in centroblasts at day 0 of the culture 
(Fig. 2). In the plasma cell cultures, there is a gradual in-
crease in mRNA for BLIMP-1, XBP-1, and IRF-4 (Fig. 2), 
consistent with previous reports (37–40). The mRNA levels 
of BLIMP-1, XBP-1, and IRF-4 increase by 15-, 30-, and 
30-fold, respectively by the end of the plasma cell culture 
compared with centroblasts. Concomitantly, mRNA encoding 
two well-known GC transcription factors, BCL-6 (19) and 
PAX-5 (41), drop  33- and 5-fold, respectively, in plasma 
cells compared with centroblasts. The mRNA for BCL-6 
and PAX-5 fall to a low level before BLIMP-1 and XBP-1 
mRNA levels increase signifi  cantly. Additionally, mRNA 
for BACH2, a GC transcription factor known to have a 
role in somatic hypermutation and class switching (42), de-
creases in the plasma cell culture. Although the length of 
time necessary for plasma cell and memory B cell diff  erentia-
tion varied among cultures, the trends in the increase and de-
crease of the transcript levels of transcription factors were the 
same in diff  erent cultures. These observations are consis-
tent with the transcriptional network described for murine 
plasma cells (8).
In the memory B cell cultures the mRNA levels of all 
three plasma cell factors, BLIMP-1, XBP-1, and IRF-4, are 
lower than in the plasma cell cultures. BLIMP-1 transcripts 
oscillate between 2–3-fold below the level in centroblasts. 
XBP-1 and IRF-4 mRNA levels increase modestly and peak 
Figure 1.  GC B cell cultures. (A) Flow cytometric analyses of repre-
sentative plasma and memory B cell cultures. Purifi  ed CD20hiCD38hi centro-
blasts (CB) were cultured with CD40L and IL-2, with IL-4 or IL-10 on HK 
cells to develop CD20+CD38− memory B cells (MEM) or CD20−CD38+ 
plasma cells (PC), respectively. Cells were harvested on the days indicated 
and stained with fl  uorescent-tagged antibodies to CD20 and CD38. The 
percentages indicate the proportion of plasma and memory B cells. Centro-
cytes (CC) are CD20+CD38+ and are present in both cultures. (B) Plasma 
cells but not memory B cells secrete high levels of IgG. Supernatant of 
plasma and memory B cell cultures were harvested on the days indicated. 
ELISA was performed to detect IgG. Cells were counted on the days 
  supernatant was collected, and the concentration of IgG per ml was 
normalized to the number of cells. (C) On day 7 of a memory B cell cul-
ture, cells were divided for culture with CD40L, IL-2, and IL-4 (memory 
B cell culture) or washed and cultured with CD40L, IL-2, and IL-10 (plasma 
cell culture). Unswitched and switched cells were analyzed with antibodies 
to CD20 and CD38 on day 11 and day 14. This is representative of two 
independent experiments.
Figure 2.  Expression kinetics of steady-state mRNA encoding 
transcription factors during memory B cell and plasma cell differ-
entiation in vitro. Cells from plasma and memory B cell cultures were 
harvested on the days indicated. Total cells were harvested and RNA was 
prepared. Quantitative RT-PCR for BCL-6, Pax5, Bach2, BLIMP-1, XBP-1, 
and IRF-4 was performed. All values were normalized to cyclophilin A and 
are shown relative to the value at day 0. Each point is the mean of tripli-
cates in qRT-PCR for each experiment. These profi  les are representative of 
three separate experiments.822  BCL-6 REPRESSES MEMORY B CELL FORMATION IN VITRO | Kuo et al.
on day 4 to 10-fold above the level found in centroblasts. After 
day 4 the mRNA for XBP-1 and IRF-4 decreases grad-
ually to be 5–7-fold above that in centroblasts. However the 
modest increase in XBP-1 and IRF-4 transcript levels in in 
vitro memory B cells compared with centroblasts suggests 
that they might play a role in memory B cell function. This 
supports a recent study showing that switched memory B cells 
defi  cient in IRF-4 do not survive well, suggesting a role for 
IRF-4 in maintaining memory B cell pool (43).
Interestingly, PAX5, BCL-6, and BACH2 mRNAs 
  decrease rapidly during diff  erentiation of memory B cells in 
vitro; the kinetics and magnitude of the decrease are similar 
to that observed during plasma cell diff  erentiation. mRNAs 
for PAX5, BCL-6, and BACH2 drop 3-, 30-, and 5-fold, 
  respectively, below the level expressed in centroblasts. Thus, 
none of the transcription factors known to be important for 
GC B cells or plasma cells were highly expressed in memory 
B cells in this culture system.
Ectopic expression of BCL-6 represses memory B cell 
differentiation in vitro
The functional role of BCL-6 in memory B cells has been 
controversial (17, 21, 44). Our data show that BCL-6 tran-
scripts fall signifi  cantly in memory B cell cultures; however, 
because BCL-6 can be regulated posttranscriptionally (45), 
we also quantitated BCL-6 protein levels in our cultures. 
Centroblasts were cultured for 3 d with or without IL-4, 
generating centrocytes or memory B cells, respectively, as 
described previously (27). Consistent with steady-state mRNA 
levels (Fig. 3 A), BCL-6 protein was also reduced in both 
centrocytes and memory B cells generated in vitro (Fig. 3 B). 
The substantial decrease in BCL-6 protein at day 3 in the in 
vitro memory B cells suggests that BCL-6 is unlikely to play 
a role in memory B cell diff  erentiation.
Because our data showed that BCL-6 levels decrease in 
in vitro memory B cells, we wished to determine if reduction 
of BCL-6 is required for memory B cell diff  erentiation. To 
do this we generated lentiviruses expressing genes encoding 
eGFP alone or a fusion protein of BCL-6 and eGFP. The 
functionality of the BCL-6–eGFP fusion protein was con-
fi  rmed in Wil-2 cells by observing a decrease of CD69 
mRNA after infection (unpublished data); CD69 is a known 
target of BCL-6 transcriptional repression (46). On day 2 of 
IL-4 and IL-10 cultures, the cells were infected with the con-
trol lentivirus expressing eGFP (Fig. 4, B–D, Control) or the 
lentivirus expressing BCL-6–eGFP (Fig. 4, B–D, BCL-6). 
3 d after infection, cells were harvested and analyzed by fl  ow 
cytometry, using GFP to identify infected cells. As expected 
(11), expression of BCL-6 blocked the formation of plasma 
cells (Fig. 4 A, left), further confi  rming the biological activity 
of the BCL-6 fusion protein. Interestingly, ectopic expres-
sion of BCL-6 also blocked in vitro memory B cell formation 
(Fig. 4 A, right). When cells were analyzed 7 d after infec-
tion, the block was more dramatic (Fig. 4 B). 9 d after in-
fection, an average of 85% of the cells were memory B cells 
in cultures infected with the control virus, whereas only an 
average of 32% of the cells were memory B cells in cultures 
infected with the BCL-6 virus.
Inhibition of in vitro memory B cell diff  erentiation in this 
experiment could have been caused by cell death or a devel-
opmental block. To investigate further, we counted live 
GFP+ cells 3 and 7 d after infection (Fig. 4 C). Cultures in-
fected with the BCL-6 virus had a slightly lower number of 
infected cells 3 d after infection. This is most likely because of 
diff  erences in infection effi   ciency of diff  erent virus stocks. 
However, 7 d after infection, BCL-6–infected cells increased 
in cell number, similar to cells infected with the control virus. 
Results from two separate experiments show that cells in both 
cultures were similarly proliferative (Fig. 4 C). We also stained 
infected cells with annexin V and 7-amino actinomycin D 
(7-AAD) to monitor apoptosis (Fig. 4 D). Five out of seven 
times analyzed, in two experiments, BCL-6–infected cells 
had small increases in numbers of annexin V+ cells; two of 
out seven times the BCL-6 cultures had equal or less apop-
totic cells (Fig. 4 D). The small diff  erence are insuffi   cient to 
explain the  50% reduction in memory B cells in BCL-6 
cultures versus control cultures on day 9. These data are 
not consistent with the possibility that apoptosis of memory 
B cells is solely responsible for their absence in the BCL-6 
cultures but provide strong support for the idea that Bcl-6 
blocks memory B cell diff  erentiation. This is consistent with 
previous reports (17, 22, 47, 48) showing that Bcl-6 in fact 
provides survival signals to GC B cells.
Figure 3.  Expression of Bcl-6 mRNA and protein is low in centro-
cyte and memory cultures. (A) Purifi  ed centroblasts at Day 0 (centro-
blasts [CB]) or cultured for 3 d with CD40L, IL-2 (centrocytes [CC]), or 
CD40L, IL-2, IL-4 (memory B cells [MEM]) were harvested and qRT-PCR 
was performed for BCL-6 and cyclophilin A. Representative of at least fi  ve 
independent experiments. Error bars correspond to the standard deviation. 
(B) Whole cell extracts of 100,000 cells from each culture described 
(see Materials and methods) were used for immunoblotting with antibod-
ies to BCL-6 and actin. Representative of two independent experiments.JEM VOL. 204, April 16, 2007  823
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Global gene expression patterns in tonsillar B cell cultures
Because none of the GC or plasma cell transcription fac-
tors we studied were expressed in the in vitro memory 
B cell cultures, we explored global gene expression patterns 
in these cultures using cDNA microarrays (5). RNA was pre-
pared from sort-purifi  ed CD38−CD20+ memory B cells and 
CD38+CD20− plasma cells generated in vitro and compared 
with CD38+CD20+ centrocytes. The relative abundance of 
transcripts in plasma cells and in vitro memory B cells was 
compared with centrocytes, and mRNAs with >1.5-fold 
diff  erential expression (P < 0.05) are listed. Complete data-
sets are provided in Tables S1–S5 (available at http://www
.jem.org/cgi/content/full/jem.20062104/DC1).
Plasma cell and centrocyte gene expression patterns
mRNAs encoding transcription factors PAX5, BACH2, 
STAT6, ID3, SPIB, ZNFN1A1 (Ikaros), EBF, and POU2F2 
(OCT2) decreased in plasma cells (Table S1). All of these 
transcription factors except for BACH2 are known to be 
down-regulated by Blimp-1 (14, 49). mRNAs for BLIMP-1, 
XBP-1, and IRF4 increased in plasma cells. In addition, the 
mRNAs for numerous XBP-1 targets including ARP, PPIB, 
ribophorin I, FKBP19, signal sequence receptor gamma, pro-
tein kinase inhibitor protein p58 and pA3 also increased in 
plasma cells (50). Ig heavy and light chain and J chain mRNAs 
were also elevated. Thus, the gene expression patterns ob-
served are consistent with previous studies of ex vivo plasma 
cells in human and mice (4, 6, 7) and of B cells with forced 
expression of Blimp-1 to drive plasmacytic diff  erentiation 
(14, 49). All the expression profi  les show that during plasma cell 
diff  erentiation B cell and proliferation gene expression pro-
grams are extinguished, whereas genes that mediate effi   cient 
immunoglobulin secretion are induced (Tables S1 and S2).
Transcripts that decreased in both plasma cells and in vitro 
memory B cells indicate genes specifi  cally expressed in GC 
B cells. Among such mRNAs were MME (CD10), LRMP 
(JAW1), Serpina9 (centerin), MKI67 (Ki67), wee1 kinase, 
BCL-6, POU2F2, SPI1, and cell cycle genes (Tables S1 and S3 
Figure 4.  Ectopic expression of BCL-6 represses memory B cell 
differentiation in vitro. Plasma and memory B cell cultures were 
infected with lentivirus encoding GFP alone (Empty Vector, Control) 
or a fusion protein of GFP and BCL-6 (BCL-6) on day 2 and harvested 
for analyses on day 5. (A) Cells were fi  rst gated for GFP expression and 
analyzed with antibodies to CD20 and CD38. Percentages represent pro-
portion of cell types (memory B cells and plasma cells) in each gated 
population. Data are representative of three experiments. (B) Graphical 
representation of the fraction of GFP+CD20+CD38− memory B cells in 
infected IL-4 B cell cultures 3 and 7 d after infection (5 and 9 total days 
in culture). Data shown are the mean of four experiments for day 5 and 
3 experiments for day 9. Error bars correspond to the standard deviation. 
(C) BCL-6–infected memory B cell cultures are similarly proliferative 
compared with memory B cells infected with the control virus. The fold 
induction in proliferation was calculated by dividing the number of 
GFP+ cells 7 d after infection by the number 3 d after infection from in 
vitro memory B cells infected with the control or BCL-6 virus. Shown 
are two independent experiments. (D) Memory B cell cultures with 
forced expression of BCL-6 and control cells have similar amounts of 
cell death. Infected memory B cell cultures were harvested on day 
5, 6 (for Expt #2), 7, and 9. Cells were analyzed for apoptosis with 
annexin V and 7-AAD staining of GFP+ cells. Graphical representation of 
annexinV+7AAD−GFP+ cells 3, 4, 5, and 7 d after infection. Shown are 
two independent experiments.824  BCL-6 REPRESSES MEMORY B CELL FORMATION IN VITRO | Kuo et al.
and Fig. 5 A), which have previously been identifi  ed as GC 
transcripts (5). Overall, the gene expression profi  les for plasma 
cells and GC B cells in culture provide further evidence that 
the developmental changes in this system closely mimic those 
that occur in vivo and further suggest many commonalities 
between human and murine B cells.
Gene expression patterns in in vitro memory B cells
Consistent with previous fi  ndings, transcript levels of anti-
apoptotic genes BCL-2 and BCL-xL (16) and costimulatory 
molecules CD80 and CD86 (15) were elevated in in vitro 
memory B cells compared with GC B cells (Fig. 5 B). Addi-
tionally, mRNAs for BIRC2 (c-IAP1) and CFLAR (c-Flip), 
which inhibit caspase activation and function (51), were ele-
vated. However, mRNAs for some proapoptotic genes, such as 
BCL-G (BCL2L14) and caspase 8, were also elevated (Fig. 5 B). 
Caspase 8 has recently been shown to play a role in the acti-
vation of NF-κB upon antigen receptor signaling and, thus, 
may not be playing a role in the apoptotic pathway in these 
cells (52). Interestingly, expression of both proapoptotic and 
antiapoptotic genes in ex vivo memory B cells has been ob-
served in a previous study (4).
Memory B cells undergo activation and proliferation 
more rapidly than naive B cells (36). Consistent with this 
phenotype, mRNAs were elevated for proteins involved in 
antigen presentation (MHC class II and CIITA), T cell co-
stimulation (CD80, CD86, OX40L, CD70, and CD40), 
chemokines to attract T cells (CXCL10, CCL17, CCL22, 
CX3C, and CCL22), and for proteins involved in JNK sig-
naling (c-jun, ATF-3, and B-ATF) and certain phosphatases. 
A striking increase in mRNAs encoding cytokine receptors 
(IL-2RB, IL-4RA, IL-12RB1, IL-13RA1, and IL-17R) was 
Figure 5.  DNA microarray analysis comparing memory B cells and 
GC B cells cultured in vitro. Each column represents data from an inde-
pendent experiment. Each row represents a gene signifi  cantly elevated 
(red) or decreased (green). A color bar shows the magnitude of gene ex-
pression changes as a ratio of expression in memory B cells versus GC 
B cells. Values shown are log2. Genes were organized into broad functional 
categories and were limited to genes with at least 1.5-fold difference 
between memory B cells and GC B cells. Unclassifi  ed genes were limited 
to genes with at least fourfold difference between memory B cells and GC 
B cells. (A) Genes decreased in memory B cells compared with GC B cells. 
(B) Genes elevated in memory B cells to GC B cells. The lists of other un-
classifi  ed genes with less than 4-fold difference but above 1.5-fold are 
available in Tables S3 and S4.JEM VOL. 204, April 16, 2007  825
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observed (Fig. 5 B), consistent with a heightened response to 
the environment.
Two comparable gene expression profi   ling studies are 
available from ex vivo human memory B cells to provide 
comparison with our results for in vitro memory B cell gene 
expression. Klein et al. (4) analyzed an ex vivo purifi  ed CD27+
CD38loCD10−CD3−CD14− population from human tonsillar 
B cells that they considered memory B cells. Alizadeh et al. 
analyzed an ex vivo purifi  ed CD20+CD27+ population from 
human peripheral blood that they considered memory B cells 
and CD38+CD77− centrocytes from the tonsils (53). This 
complete dataset is presented in Table S5. In agreement with 
our data, IL-2RB (4) and IL-13RA1 mRNA levels were found 
to be elevated in ex vivo–purifi  ed human memory B cells 
compared with centrocytes (Table S5). Stimulation via IL-4 
(54), IL-2 (54), IL-12 (55), and IL-13 (56) receptors on B cells 
is known to provide proliferation signals, but the role IL-17 
in B cells is currently not clear.
Interestingly, a group of transcription factor mRNAs 
(Stat5, TCF7, and MEF2A) known to play a role in self-
  renewal were elevated in in vitro memory B cells (Fig. 5 B). 
Stat5 has been shown by Scheeren et al. to provide self-
  renewal properties for human memory B cells (17). In a recent 
study to identify a shared transcriptional program among 
self-renewal cells, hematopoietic stem cells, memory B and T 
cells, Mef2a and members of the TCF family were shown to 
be elevated in memory B cells and hematopoietic stem cells 
(57). Although neither Mef2a nor TCF7 has been shown to 
provide self-renewal properties in memory B cells, this has 
been shown in neurons (58, 59) and stem cells (60). Thus, 
there is potential importance for the role of these transcrip-
tion factors in self-renewal of memory B cells as well.
Unexpectedly, activation-induced cytidine deaminase (AID) 
mRNA was signifi  cantly increased in in vitro memory B cells 
compared with centrocytes. AID is required for somatic 
  hypermutation that occurs in GC B cells and is known to be 
highly expressed in centroblasts (61). However, affi   nity mat-
uration continues in a primary response after the GC response 
has apparently waned (62, 63). Although it has been assumed 
that ongoing affi   nity maturation is the result of ongoing 
  selection of memory cells, our observation of high levels of 
AID in in vitro memory B cells suggests the intriguing pos-
sibility that diversifi  cation and selection may continue in 
memory B cells.
Some mRNAs showed opposite expression patterns in 
plasma cells and in vitro memory B cells (Fig. 6); those spe-
cifi  cally elevated in the memory cultures may indicate genes 
required for memory B cells. Specifi  c elevation of mRNAs 
encoding costimulatory molecules (CD40, CD80, and MHCII) 
and cytokine receptors in in vitro memory B cells is con-
sistent with the rapid reactivation of memory B cells (Fig. 
6 A). Stat5 mRNA was also increased in memory B cells 
and decreased in plasma cells generated in vitro, consistent 
with the role of Stat5 for self-renewal (17). However, BCL-6 
mRNA was not higher in memory B cells compared with 
plasma cells generated in vitro, consistent with our previous 
data (Figs. 2 and 4) and microarray of ex vivo memory 
B cells (64). Other mRNAs specifi  cally elevated in in vitro 
memory B cells include RUNX3, CCL17, TNFAIP3 (A20), 
NCOR2 (SMRT), and TRIP10 (CIP4). Elevated transcript 
Figure 6.  Genes with opposite expression patterns in plasma cells 
and memory B cells generated in vitro. (A) Bar graphs showing the ex-
pression level of genes elevated in memory B cells compared with GC B cells 
but decreased in plasma cells compared with GC B cells. (B) Bar graphs 
showing the expression level of genes elevated in plasma cells compared 
with GC B cells but decreased in memory B cells. Log2 values are shown.826  BCL-6 REPRESSES MEMORY B CELL FORMATION IN VITRO | Kuo et al.
levels of TNFAIP3 have also been seen in ex vivo memory 
B cells (Table S5). TNFAIP3 regulates NF-κB–dependent 
gene activation and apoptosis and may be important for 
memory B cell survival (65). Interestingly, transcripts encod-
ing TNFRSF17 (B cell maturation antigen [BCMA]), a re-
ceptor for B cell factors BAFF and APRIL are increased in 
plasma cells but decreased in in vitro memory B cells (Fig. 
6 B). Both c-fos and NFAT also decreased in in vitro memory 
B cells, and although not signifi  cantly elevated in our in vitro–
generated plasma cells, have been shown to be expressed in 
plasma cells. Thus, a decrease of these factors may be unique 
to memory B cells (6, 66). Another molecule known to be 
critical for plasma cells is the cyclin-dependent kinase inhi-
bitor CDKN2C (p18-INK6) (67), which is increased in 
plasma cells and decreased in memory B cells generated 
in culture (Fig. 6 B). These data provide important new in-
sights into gene expression patterns in human memory B cells 
and establish new molecular criteria for defi  ning memory 
B cell diff  erentiation.
DISCUSSION
Multiple studies have contributed to a general consensus 
about gene expression patterns in GC B cells and plasma 
cells, showing induction in plasma cells of genes encoding 
proteins involved in Ig production and secretion and repres-
sion of genes encoding proteins necessary for B cell function 
and cell division (7, 14, 50). Much less, however, is known 
about gene expression in memory B cells. We have studied 
specifi  c transcription factors and global gene expression pro-
fi  les in in vitro cultures of human B cells in which both 
plasma cells and memory B cells can be generated from GC 
B cells (27–29). Our studies reveal the kinetics with which 
key GC and plasma cell transcription factors change during 
plasma cell and memory B cell diff  erentiation in vitro. Gene 
profi  ling studies in this system confi  rm previously reported 
centrocyte and plasma cell gene expression programs and 
  reveal gene expression patterns in human memory B cells. 
These include increased transcripts encoding cytokine re-
ceptors, costimulatory molecules and transcription factors 
  including c-jun, and decreased expression of centrocyte 
  transcription factors including BCL-6. Not only is BCL-6 
mRNA extremely low in in vitro memory B cells, we show 
that ectopic expression of BCL-6 leads to formation of fewer 
memory B cells. This supports the idea that BCL-6 repres-
sion is necessary for memory B cell diff  erentiation and plasma 
cell diff  erentiation.
In vitro–generated memory B cells and the role of IL-4
The hallmarks of memory B cells include self-renewal, lon-
gevity, and rapid response upon secondary antigen encounter. 
Increased expression of known memory B cell genes CD80, 
CD86, BCL-2, and BCL-xL in our IL-4 cultures supports 
the notion that CD20+CD38− cells in this culture are similar 
to memory B cells formed in vivo.
The memory B cells that develop in our in vitro system 
are similar to those formed in vivo with respect to surface 
phenotype and the ability to generate Ig-secreting plasma 
cells rapidly (Fig. 1 C) (28). Although IL-4 drives diff  erentia-
tion of memory B cells in vitro, the role of IL-4 in the diff  er-
entiation of memory B cells in vivo is unclear. No defects 
in primary and secondary B cell responses were reported in 
IL-4–defi  cient mice (68); however, IL-13, a closely related 
cytokine that shares similar signaling pathways, could be 
compensating for the loss of IL-4 (69). It is evident from our 
microarray analysis of in vitro memory B cells that IL-4–
dependent genes are induced and it is unclear which may also 
be characteristic of in vivo memory B cells. IL-4–induced 
genes are likely to be important for memory B cells in vivo 
because IL-13RA, a known target of IL-4 (70), is up-regulated 
both in memory B cells derived from our in vitro culture in 
the presence of IL-4 and in ex vivo memory B cells in the 
absence of IL-4 (Fig. S1). Additionally, the decreased expres-
sion of many GC B cell and plasma cell genes in the memory 
B cell culture indicates diff  erentiative changes and changes in 
IL-4–dependent genes (Fig. 5).
Changes in transcription factors during memory B cell 
and plasma cell differentiation in vitro
In vitro diff  erentiation of GC B cells provided an opportunity 
to understand the dynamic changes in specifi  c transcription 
factors that occur during memory B and plasma cell formation. 
The induction of mRNA encoding late B cell regulators 
BLIMP-1, XBP-1, and IRF-4 confi  rmed our current under-
standing of the transcriptional network in plasma cells. Dur-
ing memory B cell diff  erentiation we found that BCL-6 and 
PAX5 mRNAs decreased to low levels, suggesting that these 
transcription factors do not play a role in in vitro memory 
B cells. Interestingly, decreased expression of BCL-6 and PAX5 
mRNA in in vitro memory B cells was not suffi   cient to 
  induce BLIMP-1 and XBP-1, although both are reported to 
repress BLIMP-1 and XBP-1 (46, 71). Two nonmutually ex-
clusive possibilities could explain these observations: (a) other 
repressors may control BLIMP-1 and XBP-1 transcription in 
in vitro memory B cells or (b) in addition to removal of re-
pressors, induction of activators for BLIMP-1 and/or XBP-1 
transcription may be required for plasma cell diff  erentiation. 
For example, IL-21 is known to be a strong inducer of Blimp-1 
mRNA and plasma cell diff  erentiation (72). The latter expla-
nation would suggest that for memory B cells to diff  erentiate 
quickly into plasma cells upon antigen rechallenge, only one 
signal, induction of Blimp-1 activator(s), would be required 
to initiate plasmacytic diff  erentiation, because the repressors 
Bcl-6 and PAX5 would already be absent.
Gene expression profi  le in in vitro memory B cells 
and plasma cells
Compared with GC B cells, the in vitro–generated memory 
B cells showed elevated transcripts of genes encoding co  stim-
ulatory molecules for T cells (CD40, CD80, CD86, MHCII), 
chemokines to attract T cells (CCL17, CX3C, CCL12), 
survival molecules (BCL-2, BCL-xL, BIRC2, and CFLAR), 
and self-renewal molecules (Stat5, Mef2a, TCF7). Expression JEM VOL. 204, April 16, 2007  827
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of these genes is consistent with the phenotype of memory 
B cells. Interestingly, a comparison of our data with two other 
memory B cell gene expression profi  les shows 12 similarly 
regulated genes between the study performed by Klein et al. 
(4) and our study and 18 similarly regulated genes between 
our study and the study by Alizadeh et al. (reference 53 and 
Table S5). Three genes were similarly increased in all three 
studies: c-jun, HSP70, and HLA-E. A complete list of genes 
similar among all three studies is shown in Fig. S1. The lim-
ited similarity among these studies is most likely because of 
diff  erences in the source and identifi  cation of the memory 
B cells, which could represent memory B cells at diff  erent 
stages during their diff  erentiation. It will be interesting to 
perform a time course gene expression profi  ling study using 
memory B cells from this in vitro culture system to determine 
the gene expression profi  le during memory B cell diff  erentia-
tion and to see if there will be more similarities to the other 
ex vivo gene-profi  ling studies.
Several interesting transcripts increased in plasma cells but 
decreased in memory B cells generated in vitro, including 
BCMA and p18-INK6. BCMA provides survival signals for 
long-lived plasma cells (73). The induction of BCMA tran-
scripts in plasma cells suggests that all/many post-GC plasma 
cells have the capability of becoming long-lived plasma cells 
if they fi  nd a niche in the bone marrow. Decreased BCMA 
mRNA in memory B cells suggests that memory B cells sur-
vive through activation of another receptor for BAFF and 
APRIL, probably BAFF-R (74) and/or another mechanism. 
p18-INK6 is a known regulator of cell cycle arrest in plasma 
cells (67). Decreased p18 expression in in vitro memory B cells 
suggests that p27kip, which is increased in both in vitro 
memory B cells and plasma cells, may be more important for 
dampening cell cycle in memory B cells, whereas in plasma 
cells p18 is critical.
Transcripts encoding c-fos and NFATc1 decreased only 
in in vitro memory B cells. Interestingly, both genes play a 
role in plasma cells (6, 66). Stimulation of splenic B cells from 
c-fos transgenic mice with CD40L and IL-4 resulted in the 
induction of Blimp-1 transcripts and diff  erentiation into Ig-
secreting cells (66), whereas similar treatment of wild-type 
B cells resulted in no Blimp-1 induction and minimal forma-
tion of Ig-secreting cells.
BCL-6 blocks memory B cell differentiation in vitro
BCL-6 protein is most highly expressed in GC B cells and is 
known to functionally inhibit plasma cell diff  erentiation. 
One way it does this is by inhibiting Blimp-1 transcription 
(19, 46). This is consistent with our fi  nding that ectopic ex-
pression of BCL-6 in plasma cell cultures blocks plasma 
cell diff  erentiation (Fig. 4). It was hypothesized that BCL-6 
might be required for memory B cells because BCL-6 can 
block terminal diff   erentiation and provide self-renewal 
properties (21). Our data show the contrary. BCL-6 mRNA 
in in vitro memory B cells is as low as it is plasma cells and 
BCL-6 protein is barely detectable (Fig. 6). Additionally, 
the in vitro memory B cell gene expression profi  le shows 
an increase in CDKN1B (p27), a target of BCL-6 (46). Thus, 
a function for BCL-6 in memory B cells is unlikely. Indeed, 
our data show that ectopic expression of BCL-6 in memory 
B cell cultures blocks the majority of the GC B cells from 
diff  erentiating into memory B cells. Our data, in combina-
tion with earlier studies showing Bcl-6 expression primarily 
in GC B cells (4, 10, 24, 25, 75–77) and a memory response 
in Bcl-6−/− mice (23), argue strongly against a requirement 
for Bcl-6 in memory B cell diff  erentiation. The inability of 
ectopic Bcl-6 to fully block memory B cell diff  erentiation 
in vitro may be caused by developmental heterogeneity of 
isolated tonsillar B cells that have spent varying amounts 
of time in GCs undergoing affi     nity maturation and class 
switch recombination. Alternatively, there may be a subset 
of cells (18) which can become memory cells in the presence 
of Bcl-6.
In contrast to our results, a recent study reported that 
BCL-6 provides self-renewal properties to human memory 
B cells (17). The discrepancies between the Scheeren study 
and our study are most likely because of diff  erences in memory 
B cell subpopulations being studied. To demonstrate the self-
renewal property of BCL-6, Scheeren et al. ectopically ex-
pressed BCL-6 in peripheral blood B cells cultured with cells 
expressing CD40L, IL-2, and IL-4 for 70 d. At day 70 the 
cells expressed surface molecules characteristic of GC B cells 
in our in vitro culture (CD20+CD38+) (31), although the 
authors identifi  ed these cells as memory B cells. Further stud-
ies using the same source of memory B cells and the same 
memory cell isolation will be necessary to resolve these dif-
ferences and defi  nitively establish the role of BCL-6 in mem-
ory B cell development.
In conclusion, our studies have revealed dynamic changes 
in transcription factors during terminal B cell diff  erentiation 
and have identifi  ed new gene expression programs in in vitro 
memory B cells. We show that BCL-6 is normally expressed 
at very low levels in in vitro memory B cells and that forced 
expression of BCL-6 blocks memory B cell diff  erentiation in 
culture. Our data provide validation for using this in vitro 
culture system for further analysis of B cell diff  erentiation.
MATERIALS AND METHODS
Purifi  cation of GC B cells. Tonsillar B cells were prepared and purifi  ed 
as described previously (34). Tonsils were obtained from tonsillectomies per-
formed at the Children’s Hospital of Columbia University. Tissue collection 
was approved by the Institutional Review Board of Columbia University 
Medical Center. Tonsils were shredded in RPMI plus 10% FBS (complete 
media). Media containing cells were passed through 70-μm fi  lters. Tonsillar 
cells were spun over Histopaque 1077 (Sigma-Aldrich) to obtain mono-
nuclear cells. Pelleted cells were subjected to sheep red blood cells (Colorado 
Serum Company) rosetting to deplete T cells. Aminoethylisothiouronium 
bromide (AET)–treated (Sigma-Aldridch) sheep red blood cell were incu-
bated with tonsillar B cells on ice for 1 h. Resuspended AET-treated cells 
were spun over Histopaque 1077. The resulting nonrosetted cells in the in-
terphase contained >95% CD19+ cells. Centroblasts were isolated by mag-
netic cell separation (Miltenyi Biotec), and purifi   cation was performed 
according to manufacturer’s protocol. CD19+ cells were incubated with anti-
bodies to IgD (1.5 μg/30 × 106 cells) and CD44 (1.5 μg/30 × 106 cells) 
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rat anti–mouse IgG2a/IgG2b microbeads (Miltenyi Biotec) in MACS buff  er 
for 15 min on ice. The negatively selected cells were collected.
GC B cell culture. HK cells were a kind gift from Dr. Yong Sung Choi 
(Alton Ochsner Medical Foundation, New Orleans, LA). Cytokines IL-2, 
IL-4, and IL-10 were obtained from Peprotech. Concentrations used for the 
cultures were 25 ng/ml for IL-2, 50 ng/ml for IL-4, and 100 ng/ml for 
IL-10. Soluble human trimeric CD40L was obtained from Amgen and used at 
a concentration of 400 ng/ml. In brief, 3,000 HK cells/well/ml were plated 
in 24-well plates the day before culture of tonsillar B cells. On day 0, 600,000 
centroblasts were cocultured with HK cells per ml of ISCOV media with 
relevant cytokines depending on culture, and cells were recultured every 
3–5 d with new HK cells and cytokines. Subsequent reculturing of cells was 
plated at 300,000 cells/ml/well.
The following antibodies were used for fl  ow cytometry: FITC-CD19 
(Becton Dickinson), PE-CD19 (Southern Biotechnology Associates, Inc.), 
FITC-CD44 (Becton Dickinson), PE-CY7-CD20 (eBioscience), PE-CD20 
(Becton Dickinson), and CD38 (Becton Dickinson). All antibodies were 
used at 1:100 except for PE-CY7-CD20, which was used at 1:5.
Lentiviral infections. FUW-hBCL6 was constructed by inserting hBCL-6 
into SalI–BamHI site of pEGFP-C1. The construct was digested and blunted 
at the NheI and BamHI sites to generate a fragment containing eGFP–BCL-6. 
Blunted eGFP–BCL-6 fragment was cloned into blunted BamHI–EcoRI 
sites of FUGW (a gift from Dr. Jeremy Luban, Columbia University).
293T cells (at 75–80% confl  uency) were cotransfected with 10 μg of 
pHD8.9, a lentiviral packaging construct (provided by Dr. Jeremy Luban, 
Columbia University), 5 μg of vesicular stomatitis virus G protein expres-
sion vector (provided by Dr. S.P. Goff  , Columbia University), and 10 μg of 
either FUW–BCL-6 or FUGW using calcium phosphate precipitation. Len-
tiviral supernatants were collected 48 h after transfection concentrated and 
titered. GC B cells were infected at a multiplicity of infection of 1–2.
Quantitative PCR. RNAs were isolated using TRIzol Reagent (Life 
Technologies), and cDNAs were prepared using SuperScript III reverse 
Trasncriptase (Invitrogen), according to the manufacturer’s protocol. Quan-
titative RT-PCRs were performed on Abi7700 (Applied Biosystems). Con-
centrations for stock reagents are as follows: PCR buff  er, 200 μM dNTP, 
0.4× SYBR Green (Sigma-Aldrich), 150 nM 6-carboxy-x-rhodamine, ROX 
(Sigma-Aldrich), 1% DMSO, and 1.25 U Taq polymerase in 25 μl. Condi-
tions and primer concentrations are listed in Table S6. The amplifi  cation 
programs are as follows: 95°C for 5 min; 95°C for 20 s, 59°C for 1 min, and 
80–87°C (depending on primer) for 20 s (data collected) for 40 cycles. The 
melting curves are as follows: 95°C for 20 s, 59°C for 15 s, and up to 95°C 
for 20 s with a 19-min ramping time.
Apoptosis staining of cells with annexin V and 7-AAD. Cells were in-
fected on day 2 and harvested on day 5, washed twice with cold PBS. Cells were 
resuspended in annexin V buff  er (Becton Dickinson) and incubated with annexin 
(Becton Dickinson) at 5 μl/100 μl buff  er/105 cells and 5 μl VIA-PROBE 
(7AAD; Becton Dickinson) for 15 min at room temperature.
Protein expression analysis. Detection of BCL-6 (Santa Cruz Bio-
technology) and actin (Sigma-Aldrich) by Western blotting were performed 
  using whole cell lysates of 100,000 cultured cells. BCL-6 antibody was used 
at 1:500 and actin antibody was used at 1:1,000.
Microarray procedures. Fluorescent cDNA probes were prepared from 
an experimental mRNA sample (Cy5 labeled) and a control mRNA sample 
(Cy3 labeled) isolated from a pool of lymphoma cell lines. The use of a com-
mon control cDNA probe allows the relative expression of each gene to be 
compared across all samples. Microarray analysis was performed as described 
in Shaff  er et al. (46) using 25–50 μg of polyA+ RNA (FastTrack; Invitrogen) 
for each cellular population. Arrays for each culture systems were repeated 
three times with independent pools.
Microarray analysis. All listed genes are statistically signifi  cant (P < 0.05) as 
determined by three microarray replicates for each population of cells. Genes are 
grouped into functional categories with at least 1.5-fold diff  erence between two 
cellular populations, and uncategorized genes have at least a fourfold diff  erence 
between two memory B cells and GC B cells. The raw data is available at GEO 
(http://www.ncbi.nlm.nih.gov/geo) under series accession no. GSE7128. 
Online supplemental material. DNA microarray analysis comparing 
plasma or memory B cells to centrocytes. Values from three independent ar-
rays for each cell population were averaged and then the averages for two 
populations were compared. Genes were limited to genes with at least 1.5-
fold diff  erence between two populations of cells with a p-value < 0.05. Log2 
values are shown for each gene. The genes are arranged in order of the most 
to least diff  erence in level between two cellular populations. Figure S1 shows 
similar genes elevated in memory B cells compared with GC B cells among 
three independent studies. A Venn diagram showing genes elevated in mem-
ory B cells comparing two studies and all three studies. Group A is genes 
from the current study, group B is data from Alizadeh et al. (53), and group 
C represents the study performed as described in reference 4. Table S1 shows 
genes decreased in plasma cells as compared with centrocytes. Table S2 
shows genes elevated in centrocytes compared with plasma cells. Table S3 
shows genes decreased in in vitro memory B cells compared with centro-
cytes. Table S4 shows genes elevated in centrocytes compared with in vitro 
memory B cells. Table S5 shows genes elevated in ex vivo CD20+CD27+ 
memory B cells compared with ex vivo CD38+CD77− centrocytes. Table 
S6 shows sequences and concentration of primers used for qRT-PCR.
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